AcquisitionOther
Lyell Immunopharma, Inc. acquired ImmPACT Bio
Public deal record from 8-K. The source names the buyer and target, and terms are shown only when the filing or announcement discloses them.
Deal tape row
Lyell Immunopharma, Inc. -> ImmPACT Bio · $30 million
The acquisition of ImmPACT is expected to significantly strengthen Lyells clinical-stage pipeline of next- generation CAR T-cell therapies and complement its suite of proprietary technologies designed to generate longer-lasting, functional T cells to achieve
Open source record (SEC) ↗